Cytori Therapeutics, Inc. (CYTX)

[figaruch]

On March 6, 2018, the Company received a letter from Nasdaq granting the Company an additional compliance period of 180 calendar days, or until September 4, 2018, in which to regain compliance. Nasdaq granted the additional compliance period after the Company continued to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the Bid Price Requirement, and we provided notice to Nasdaq of our intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary.